Carmen Chamorro-Martinez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.

Journal: Future oncology (London, England)
Published: August 30, 2026

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Journal: Haematologica
Published: July 07, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica
Published: March 10, 2026

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Journal: Blood
Published: February 05, 2026

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Journal: Blood neoplasia
Published: October 15, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances
Published: September 18, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances
Published: September 18, 2025

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.

Journal: Blood
Published: November 07, 2024

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.

Journal: The Lancet. Haematology
Published: August 29, 2024

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.

Journal: Blood
Published: December 18, 2023

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Journal: Cancer medicine
Published: February 10, 2023
Showing 1-12 of 17

Last Updated: 09/26/2026